Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 19/20 | 0.74 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | HMGCR | P04035 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7720729 | 0.91 | GCGR (0.86) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL6871563 | 0.86 | GCGR (0.74) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL3445407 | 0.86 | GCGR (0.78) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL6953288 | 0.85 | GCGR (1.00) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL3407031 | 0.83 | GCGR (0.69) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL15029058 | 0.82 | GCGR (0.73) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL7077308 | 0.82 | GCGR (0.67) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL18947969 | 0.81 | GCGR (0.70) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL12074145 | 0.81 | GCGR (0.66) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL18947967 | 0.81 | GCGR (0.70) | GCGRESR1HMGCRCHRM1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8471045-B2 | Synthesis of statins | LEK PHARMACEUTICALS D.D. (SI) | 2013-06-25 | — | — | US | disclosed |
| US-8404870-B2 | ((2S,4R)-4,6-dihydroxytetrahydro-2H-pyran-2-yl)methyl carboxylate and process for the production thereof | LEK PHARMACEUTICALS D.D. (SI) | 2013-03-26 | — | — | US | disclosed |
| US-8404870-B2 | ((2S,4R)-4,6-dihydroxytetrahydro-2H-pyran-2-yl)methyl carboxylate and process for the production thereof | LEK PHARMACEUTICALS D.D. (SI) | 2013-03-26 | — | — | US | disclosed |
| US-8404841-B2 | Process for the preparation of statins and their pharmaceutically acceptable salts thereof | MSN LABORATORIES LIMITED (IN) | 2013-03-26 | — | — | US | disclosed |
| US-8354530-B2 | Preparation of HMG-CoA reductase inhibitors, in particular rosuvastatin calcium, introducing L-malic acid as source of chirality for side chain; statin core moiety is consecutively coupled with chiral segment containing 4 carbon atoms and segment containing 2 carbon atoms; treating hypercholesterolemia | Lek Pharmaceuticals d. d (SI) | 2013-01-15 | — | — | US | disclosed |
| US-8269001-B2 | Process for the synthesis of HMG-CoA reductase inhibitors | LEK PHARMACEUTICALS D.D. (SI) | 2012-09-18 | — | — | US | disclosed |
| US-8269001-B2 | Process for the synthesis of HMG-CoA reductase inhibitors | LEK PHARMACEUTICALS D.D. (SI) | 2012-09-18 | — | — | US | disclosed |
| US-20120196333-A1 | SYNTHESIS OF STATINS | LEK PHARMACEUTICALS D.D. (SI) | 2012-08-02 | — | — | US | disclosed |
| US-20120196333-A1 | SYNTHESIS OF STATINS | LEK PHARMACEUTICALS D.D. (SI) | 2012-08-02 | — | — | US | disclosed |
| US-8183397-B2 | Synthesis of statins | LEK PHARMACEUTICALS D.D. (SI) | 2012-05-22 | — | — | US | disclosed |
| US-20110178295-A1 | SYNTHESIS OF STATINS | LEK PHARMACEUTICALS D.D. (SI) | 2011-07-21 | — | — | US | disclosed |
| US-20110178295-A1 | SYNTHESIS OF STATINS | LEK PHARMACEUTICALS D.D. (SI) | 2011-07-21 | — | — | US | disclosed |
| US-20110046375-A1 | ((2S,4R)-4,6-DIHYDROXYTETRAHYDRO-2H-PYRAN-2-YL)METHYL CARBOXYLATE AND PROCESS FOR THE PRODUCTION THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2011-02-24 | — | — | US | disclosed |
| US-20110046375-A1 | ((2S,4R)-4,6-DIHYDROXYTETRAHYDRO-2H-PYRAN-2-YL)METHYL CARBOXYLATE AND PROCESS FOR THE PRODUCTION THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2011-02-24 | — | — | US | disclosed |
| US-20100056783-A1 | Novel Process for the Preparation of Statins and their Pharmaceutically Acceptable Salts thereof | MSN LABORATORIES LIMITED (IN) | 2010-03-04 | — | — | US | disclosed |
| US-20090275752-A1 | Novel Process for Statins and its Pharmaceutically Acceptable Salts Thereof | MSN LABORATORIES LIMITED (IN) | 2009-11-05 | — | — | US | disclosed |
| US-20090275752-A1 | Novel Process for Statins and its Pharmaceutically Acceptable Salts Thereof | MSN LABORATORIES LIMITED (IN) | 2009-11-05 | — | — | US | disclosed |
| US-20080300406-A1 | Process for the Synthesis of Hmg-Coa Reductase Inhibitors | LEK PHARMACEUTICALS D.D. (SI) | 2008-12-04 | — | — | US | disclosed |
| US-20080300406-A1 | Process for the Synthesis of Hmg-Coa Reductase Inhibitors | LEK PHARMACEUTICALS D.D. (SI) | 2008-12-04 | — | — | US | disclosed |
| US-20080255170-A1 | Process for the Synthesis of Rosuvastatin Calcium | LEK PHARMACEUTICALS D.D (SI) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046375-A1 | ((2S,4R)-4,6-DIHYDROXYTETRAHYDRO-2H-PYRAN-2-YL)METHYL CARBOXYLATE AND PROCESS FOR THE PRODUCTION THEREOF | HMGCR, CYP4A11, CYP4B1 | GCGR 2629/4885ESR1 4120/4885HMGCR 1/4885 |
| US-20080255170-A1 | Process for the Synthesis of Rosuvastatin Calcium | HMGCR, ME1, COASY | GCGR 3070/4885ESR1 3656/4885HMGCR 1/4885 |
| US-20100056783-A1 | Novel Process for the Preparation of Statins and their Pharmaceutically Acceptable Salts thereof | HMGCR, PCSK9, NPC1L1 | GCGR 972/4885ESR1 4725/4885HMGCR 1/4885 |
| US-20110178295-A1 | SYNTHESIS OF STATINS | HMGCR, DHCR7, COASY | GCGR 2504/4885ESR1 3340/4885HMGCR 1/4885 |
| US-20120196333-A1 | SYNTHESIS OF STATINS | HMGCR, DHCR7, COASY | GCGR 2504/4885ESR1 3340/4885HMGCR 1/4885 |
| US-20090275752-A1 | Novel Process for Statins and its Pharmaceutically Acceptable Salts Thereof | HMGCR, NPC1L1, PCSK9 | GCGR 1528/4885ESR1 4822/4885HMGCR 1/4885 |
| US-20080300406-A1 | Process for the Synthesis of Hmg-Coa Reductase Inhibitors | HMGCR, COASY, LSS | GCGR 1741/4885ESR1 3703/4885HMGCR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.